Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Meeting Report
  • Published:

International Society for Cell and Gene Therapy of Cancer: 2005 meeting in Shenzhen, China

Cancer Gene Therapy volume 14, pages 128–138 (2007)Cite this article

Abstract

The 2005 International Society for Cell and Gene Therapy of Cancer (ISCGT) Congress was held in Shenzhen, China (www.iscgtchina2005.com) from December 9th–11th 2005. Here, we describe a representation of the most seminal presentations providing an overview of the progress in the field of cancer gene therapy including the successful introduction of the first approved gene therapy drug.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Abbreviations

AC:

acid ceramidase

BBB:

blood brain barrier

CD:

cytosine deaminase

CD40L:

CD40 ligand

CTL:

cytotoxic T lymphocyte

DC:

dendritic cell

ESGT:

European Society for Gene Therapy

ES-SCLC:

extensive stage – small cell lung carcinoma

FasL:

Fas ligand

HCC:

hepatocellular cancer

HNSCC:

head and neck small cell carcinoma

HSV:

herpes simplex virus

i.p.:

intraperitoneal

ISCGT:

International Society for Cell and Gene Therapy of Cancer

i.v.:

intravenous

LN:

lymph node

LTR:

long terminal repeat

MK:

Midkine

MLV:

murine leukemia virus

MMTV:

mouse mammary tumor virus

NK:

natural killer

NPC:

nasopharyngeal carcinoma

RCR:

replication-competent retrovirus

RSV:

Rous Sarcoma Virus

s.c.:

subcutaneous

TAA:

tumor associated antigen

TACE:

transcatheter hepatic arterial

TILs:

tumor infiltrating lymphocytes

Tregs:

regulatory/suppressor T cells

v.p.:

viral particle

VSV:

vesicular stomatitis virus

References

  1. Peng Z . Current status of Gendicine in China: recombinant human Ad-p53 agent for the treatment of cancer. Hum Gene Ther 2005; 16: 1016–1027.

    Article  CAS  PubMed  Google Scholar 

  2. Roth JA . Adenovirus p53 gene therapy. Expert Opin Biol Ther 2006; 6: 55–61.

    Article  CAS  PubMed  Google Scholar 

  3. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12: 878–887.

    Article  CAS  PubMed  Google Scholar 

  4. Hyer ML, Sudarshan S, Schwartz DA, Hannun Y, Dong JY, Norris JS . Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther 2003; 10: 330–339.

    Article  CAS  PubMed  Google Scholar 

  5. Tagawa M, Kawamura K, Shimozato O, Ma G, Li Q, Suzuki N et al. Virology- and immunology-based gene therapy for cancer. Cancer Immunol Immunother 2006; 55: 1420–1425.

    Article  CAS  PubMed  Google Scholar 

  6. Kyte JA, Gaudernack G . Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother 2006; 55: 1432–1442.

    Article  CAS  PubMed  Google Scholar 

  7. Guo Y, Zhang J, Zheng Y, Tao X, Chen C, Liu S et al. A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem 2005; 280: 41940–41952.

    Article  CAS  PubMed  Google Scholar 

  8. Guelen L, Paterson H, Gäken J, Meyers M, Farzaneh F, Tavassoli M . TAT-Apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene 2004; 23: 1153–1165.

    Article  CAS  PubMed  Google Scholar 

  9. Gyorffy B, Serra V, Jurchott K, Abdul-Ghani R, Garber M, Stein U et al. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 2005; 24: 7542–7551.

    Article  PubMed  Google Scholar 

  10. Dietel M, Sers C . Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. Virchows Arch 2006; 448: 744–755.

    Article  PubMed  Google Scholar 

  11. Tang Y, Zhang L, Yuan J, Akbulut H, Maynard J, Linton PJ et al. Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens. Blood 2004; 104: 2704–2713.

    Article  CAS  PubMed  Google Scholar 

  12. Wei WZ, Morris GP, Kong YC . Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 2004; 53: 73–78.

    Article  CAS  PubMed  Google Scholar 

  13. Schubert LA, Jeffery E, Zhang Y, Ramsdell F, Ziegler SF . Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem 2001; 276: 37672–37679.

    Article  CAS  PubMed  Google Scholar 

  14. Löhr JM, Hoffmeyer A, Kröger J-C, Freund M, Hain J, Holle A et al. Microencapsulated cell mediated therapy of inoperable pancreatic carcinoma. Lancet 2001; 357: 1591–1592.

    Article  PubMed  Google Scholar 

  15. Löhr JM, Kröger J-C, Hoffmeyer A, Freund M, Hain J, Holle A et al. Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable pancreatic carcinoma in a phase I/II trial. Cancer Ther 2003; 1: 121–131.

    Google Scholar 

  16. Günzburg WH, Salmons B . Cell and gene therapy to improve cancer treatment. Acta Biochim Pol 2005; 52: 601–607.

    PubMed  Google Scholar 

  17. Rubinchik S, Yu H, Woraratanadharm J, Voelkel-Johnson C, Norris JS, Dong JY . Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther 2003; 10: 814–822.

    Article  CAS  PubMed  Google Scholar 

  18. Hedley SJ, Chen J, Mountz JD, Li J, Curiel DT, Korokhov N et al. Targeted and shielded adenovectors for cancer therapy. Cancer Immunol Immunother 2006; 55: 1412–1419.

    Article  CAS  PubMed  Google Scholar 

  19. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW . Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Therapy 2001; 8: 341–348.

    Article  CAS  PubMed  Google Scholar 

  20. Nesbeth D, Williams SL, Chan L, Brain T, Slater NK, Farzaneh F et al. Metabolic biotinylation of lentiviral pseudotypes for scalable paramagnetic microparticle-dependent manipulation. Mol Ther 2006; 13: 814–822.

    Article  CAS  PubMed  Google Scholar 

  21. Chan L, Hardwick NR, Guinn BA, Darling D, Gaken J, Galea-Lauri J et al. An immune edited tumour versus a tumour edited immune system: prospects for immune therapy of acute myeloid leukaemia. Cancer Immunol Immunother 2006; 55: 1017–1024.

    Article  CAS  PubMed  Google Scholar 

  22. Chan L, Hardwick N, Darling D, Galea-Lauri J, Gaken J, Devereux S et al. IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol Ther 2005; 11: 120–131.

    Article  CAS  PubMed  Google Scholar 

  23. Chan L, Nesbeth D, Mackey T, Galea-Lauri J, Gaken J, Martin F et al. Conjugation of lentivirus to paramagnetic particles via nonviral proteins allows efficient concentration and infection of primary acute myeloid leukemia cells. J Virol 2005; 79: 13190–13194.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hao JS, Shan BE . Immune enhancement and anti-tumour activity of IL-23. Cancer Immunol Immunother 2006; 55: 1426–1431.

    Article  CAS  PubMed  Google Scholar 

  25. Chua AO, Chizzonite R, Desai BB, Truitt TP, Nunes P, Minetti LT et al. Expression cloning of a human IL-12 receptor component: A new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 1994; 153: 128–136.

    CAS  PubMed  Google Scholar 

  26. Tangney M, Casey G, Larkin JO, Collins CG, Soden D, Cashman J et al. Non-viral in vivo immune gene therapy of cancer: combined strategies for treatment of systemic disease. Cancer Immunol Immunother 2006; 55: 1443–1450.

    Article  CAS  PubMed  Google Scholar 

  27. Van Beusechem VW, Van den Doel PB, Grill J, Pinedo HM, Gerritsen WR . Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002; 62: 6165–6171.

    CAS  PubMed  Google Scholar 

  28. Geoerger B, Vassal G, Opolon P, Dirven CMF, Morizet J, Laudani L et al. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdD24–p53 against human malignant glioma. Cancer Res 2004; 64: 5753–5759.

    Article  CAS  PubMed  Google Scholar 

  29. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy 2003; 10: 292–303.

    Article  CAS  PubMed  Google Scholar 

  30. Simpson GR, Han Z, Liu B, Wang Y, Campbell G, Coffin RS . Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res 2006; 66: 4835–4842.

    Article  CAS  PubMed  Google Scholar 

  31. Weber E, Anderson WF, Kasahara N . Recent advances in retrovirus-mediated gene therapy: teaching an old vector new tricks. Curr Opin Mol Ther 2001; 3: 439–453.

    CAS  PubMed  Google Scholar 

  32. Logg CR, Logg A, Matusik R, Bochner BH, Kasahara N . Tissue-specific targeting of replication-competent retrovirus vectors by transcriptional regulation. J Virol 2002; 76: 12783–12791.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wang, WJ, Tai CK, Kasahara N, Chen TC . Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther 2003; 14: 117–127.

    Article  CAS  PubMed  Google Scholar 

  34. Solly SK, Trajcevski S, Frisen C, Holzer GW, Nelson E, Clerc B et al. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther 2003; 10: 30–39.

    Article  CAS  PubMed  Google Scholar 

  35. Tai CK, Wang W, Chen T, Kasahara N . Single-shot, multi-cycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther 2005; 12: 842–851.

    Article  CAS  PubMed  Google Scholar 

  36. Hlavaty J, Stracke A, Klein D, Salmons B, Günzburg WH, Renner M . Multiple modifications allow high titer, tissue-specific retroviral vector production. J Virol 2004; 78: 1384–1392.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Hlavaty J, Portsmouth D, Stracke A, Salmons B, Gunzburg WH, Renner M . Effects of sequences of prokaryotic origin on titer and transgene expression in retroviral vectors. Virology 2004; 330: 351–360.

    Article  CAS  PubMed  Google Scholar 

  38. Hlavaty J, Schittmayer M, Stracke A, Jandl G, Knapp E, Felber BK et al. Effect of post-transcriptional regulatory elements on transgene expression and virus production in the context of retrovirus vectors. Virology 2005; 341: 1–11.

    Article  CAS  PubMed  Google Scholar 

  39. Indik S, Günzburg WH, Salmons B, Rouault F . Mouse mammary tumor virus infects human cells. Cancer Res 2005; 65: 6651–6659.

    Article  CAS  PubMed  Google Scholar 

  40. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497.

    Article  CAS  PubMed  Google Scholar 

  41. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255–256.

    Article  PubMed  Google Scholar 

  42. Blancafort P, Segal DJ, Barbas III CF . Designing transcription factor architectures for drug discovery. Mol Pharmacol 2004; 66: 1361–1371.

    Article  CAS  PubMed  Google Scholar 

  43. Tan W, Dong Z, Wilkinson TA, Barbas III CF, Chow SA . Human immunodeficiency virus type-1 incorporated with fusion proteins consisting of integrase and the designed polydactyl zinc-finger protein E2C can bias integration of viral DNA into a predetermined chromosomal region in human cells. J Virol 2006; 80: 1939–1948.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ . Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62: 4656–4662.

    CAS  PubMed  Google Scholar 

  45. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003; 63: 2462–2469.

    CAS  PubMed  Google Scholar 

  46. Dingli D, Peng KW, Harvey ME, Greipp PR, O’Connor MK, Cattaneo R et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641–1646.

    Article  CAS  PubMed  Google Scholar 

  47. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005; 23: 209–214.

    Article  CAS  PubMed  Google Scholar 

  48. Hallak LK, Merchan JR, Storgard CM, Loftus JC, Russell SJ . Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression. Cancer Res 2005; 65: 5292–5300.

    Article  CAS  PubMed  Google Scholar 

  49. Shinosaki K, Ebert O, Woo SLC . Treatment of colorectal carcinoma metastatic to the rat liver by hepatic artery injection of oncolytic vesicular stomatitis virus. Int J Can 2005; 114: 659–664.

    Article  Google Scholar 

  50. Shinosaki K, Ebert O, Woo SLC . Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 2005; 41: 196–203.

    Article  Google Scholar 

  51. Shinozaki K, Ebert O, Suriawinata A, Thung S, Woo SLC . Prophylactic IFN-alpha treatment increases the therapeutic index of oncolytic VSV virotherapy for advanced hepatocellular carcinoma in immune competent rats. J Virol 2005; 79: 13705–13713.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Rosenberg SA, Yang JC, Restifo NP . Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909–915.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Gershon RK, Cohen P, Hencin R, Liebhaber SA . Suppressor T cells. J Immunol 1972; 108: 586–590.

    CAS  PubMed  Google Scholar 

  54. Gershon RK, Mokyr MB, Mitchell MS . Activation of suppressor T cells by tumour cells and specific antibody. Nature 1974; 250: 594–596.

    Article  CAS  PubMed  Google Scholar 

  55. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T . Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985; 161: 72–87.

    Article  CAS  PubMed  Google Scholar 

  56. Shimizu J, Yamazaki S, Sakaguchi S . Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211–5218.

    CAS  PubMed  Google Scholar 

  57. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942–949.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Noriyuki Kasahara for his help with this manuscript. The 2005 ISCGT China meeting was made possible through the dedicated efforts of Miss Katherine Lindley and Miss Suzanne McGrath; Support from Shenzhen SiBiono GeneTech; ISCGT; Centre for Cell, Gene, and Vaccine Therapy; Medical University of South Carolina; Bridgetech Holdings International; Vector Gene Technology Company Ltd, Beijing Pharmaceutical Group; Leukaemia Research Fund and the Department of Health in the UK to BG.

Author information

Authors and Affiliations

  1. Department of Haematological Medicine, King's College London School of Medicine, The Rayne Institute, London, UK

    B A Guinn & F Farzaneh

  2. Department of Microbiology and Immunology, BSB Medical University of South Carolina, Charleston, SC, USA

    J S Norris

  3. Sidney Kimmel Cancer Center, 10835 Road to the Cure, San Diego, CA, USA

    A B Deisseroth

Authors
  1. B A Guinn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J S Norris
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Farzaneh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A B Deisseroth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B A Guinn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guinn, B., Norris, J., Farzaneh, F. et al. International Society for Cell and Gene Therapy of Cancer: 2005 meeting in Shenzhen, China. Cancer Gene Ther 14, 128–138 (2007). https://doi.org/10.1038/sj.cgt.7700996

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700996

Keywords

This article is cited by

Search

Advanced search

Quick links